Latest Conference Content

A clinical pharmacy specialist with the Department of Veterans Affairs (VA) described how the department is trying to address the needs of female veterans, including their reproductive health, as well as addressing disparities in chronic diseases.

Intravenous (IV) robotic technology brings advantages for pharmacy staff, but there are also accuracy issues with the technology. In addition, this technology will not be replacing a pharmacy technician job, said Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA, director of pharmacy cancer care and assistant professor of pharmacy, Mayo Clinic.

The increasing complexity and costs of oncology care and resulting patient financial toxicity is driving more health systems to adopt oncology stewardship principles in their pharmacy practices, according to a session at the American Society of Health-System Pharmacists (ASHP) 2022 Midyear Clinical Meeting & Exposition.

Neil Iyengar, MD, from Memorial Sloan Kettering Cancer Center, is expecting updates on therapies to fight human epidermal growth factor 2 (HER2)–positive breast cancer and novel antibody drug conjugates at the upcoming San Antonio Breast Cancer Symposium (SABCS).

The annual San Antonio Breast Cancer Symposium (SABCS) will once again take place in a hybrid fashion, with in-person attendees returning to the Henry B. Gonzales Convention Center to hear the latest clinical and basic research, as well as see several of their peers receive awards for their contributions to the space.

Because of the COVID-19 pandemic, the last 2 years have been virtual; the organization previously met in Las Vegas in 2019 and 2016.

Marie A. Chisholm-Burns, PharmD, PhD, MPH, MBA, FCCP, FASHP, FAST, executive vice president and provost at Oregon Health and Science University, is receiving the award, which is presented to individuals who demonstrate excellence in pharmacy practice leadership.

At the American Society of Health-System Pharmacists (ASHP) 2022 Midyear Clinical Meeting & Exposition, Angela M. Hill, PharmD, CPh, RPh, professor and associate dean of clinical affairs; project director, WE-CARE, University of South Florida Taneja College of Pharmacy, will receive the ASHP-ABHP Joint Leadership award for her leadership in addressing health equities.

Data on empagliflozin in chronic kidney disease (CKD) showed the drug had similar efficacy across subgroups, but more data is needed to really understand the benefit of the drug in CKD, said Jennifer Green, MD, professor of medicine at Duke University School of Medicine, member of Duke Clinical Research Institute, and EMPA-KIDNEY collaborator.

The studies reviewed estimates of economic and humanistic impact on both patients with chronic kidney disease (CKD) as well as their caregivers.

Former Obama administration official Kavita Patel, MD, MS, told a gathering of the OneOncology Physician Leadership Conference that policy leaders and members of Congress need input on the realities of oncology practice finances.

Edward Licitra, MD, PhD, who is CEO of Astera Cancer Care, based in East Brunswick, New Jersey, and Edward “Ted” Arrowsmith, MD, of the Chattanooga office, Tennessee Oncology, shared ideas during a panel discussion at the OneOncology Physician Leadership Conference, held Friday through Sunday in Nashville, Tennessee. Sheri Chatterson, MSM, MBA, CFHP, vice president of payer relations at OneOncology, led the discussion.

Jeff Patton, MD, CEO of OneOncology, kicks off the first annual Physician Leadership Conference by outlining the competitive challenges for community practices and leads a discussion with Adam Boehler, former head of the Center for Medicare and Medicaid Innovation.

The disease groups that make up the OneOncology clinical pathways program cover 90% of patients with cancer and develop best practices for treating cancer in the majority of patients, said Edward “Ted” Arrowsmith, MD, MPH, managing partner and director of research, East Tennessee Division, Tennessee Oncology.

The OneOncology Annual Conference is being held November 11-13 in Nashville, Tennessee, and brings together practice leaders, physicians, and advanced practice providers to discuss the business of oncology and scientific advancements, explained Davey Daniel, MD, chief medical officer of OneOncology.

For the US health care system to be appropriately patient-centered, clinical trials need to be reflective of the country's diversity, said Joseph Alvarnas, MD, vice president of government affairs and senior medical director for employer strategy at City of Hope.

Debra Patt, MD, PhD, MBA, executive vice president of public policy and strategic initiatives at Texas Oncology, expands on her keynote address at the 2022 meeting of Patient-Centered Oncology Care®, which focused on DESTINY-Breast04 study findings and their applicability to managed care.

Representatives across 12 disease groups make up a council that sets clinical recommendations for oncology care and those decisions are being pushed out in the electronic medical record for decision support at the point of care, said Jeffrey Patton, MD, CEO, OneOncology, and executive chairman of the board, Tennessee Oncology. Patton will lead off OneOncology's Physician Leadership Conference, which runs November 11-13 in Nashville.

Ishani Ganguli, MD, MPH, assistant professor of medicine at Harvard Medical School, physician at Brigham and Women’s Hospital, reacts to receiving the 2022 Seema S. Sonnad Emerging Leader in Managed Care Research Award.

Population health brings an important lens to both oncology practice and research, said Neil Iyengar, MD, associate attending physician, breast medical service, Memorial Sloan Kettering Cancer Center.

A panel including several experts in cardiology discussed the ways that heart failure (HF) can be diagnosed and treated using the new 2022 AHA/ACC/HFSA Guidelines.

Patient-Centered Oncology Care® (PCOC) begins Wednesday in Tennessee with 2 days of discussions on how to achieve the related goals of closing health care disparities and eliminating barriers for patients.

Kashyap Patel, MD, president of Community Oncology Alliance and chief executive officer of Carolina Blood and Cancer Care Associates, previews the Patient-Centered Oncology Care® (PCOC) 2022 meeting happening this week in Nashville, Tennessee.

Tochi M. Okwuosa, DO, cardiologist and director of cardio-oncology at Rush University Medical Center, delivered several presentations at the American Heart Association’s Scientific Sessions this year. Chief among them were the importance of cardiovascular health in cancer survivors and cardio-toxicity from cancer treatments.

Kausik K. Ray, MB ChB, MD, MPhil, is professor of public health and a consultant cardiologist at Imperial College London in the United Kingdom. At this year’s American Heart Association’s Scientific Sessions, he presented findings from a 4-year open-label extension study of inclisiran, a small interfering RNA that targets proprotein convertase subtilisin kexin type 9 to lower low-density lipoprotein cholesterol (LDL-C).

Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA, professor of medicine and the Gerald S. Berenson Endowed Chair in Preventative Cardiology, Tulane University School of Medicine, discusses the results of the recently halted FRESH trial, why there is such a great need for new antihypertensive agents, and possible contributory factors to outcome disparities between Black and White patients.

Posters presented at the American Heart Association's Scientific Sessions elaborated on the results of out-of-pocket expenses and adherence for guideline-directed medical therapies in patients with heart failure with reduced ejection fraction (HFrEF).

The DELIVER trial is the largest trial to date of SGLT2 inhibitor use in heart failure, and these latest data on dapagliflozin in heart failure with mildly reduced or preserved ejection fraction show an extensive benefit on health status, noted Mikhail Kosiborod, MD, cardiologist at St. Luke's Mid America Heart Institute in Kansas City, Missouri.

A panel at the annual American Heart Association conference held in Chicago, Illinois, discussed ways in which cardiovascular disease (CVD) care was affected by equity issues between White and Black patients.

The latest real-world clinical practice data from the VICTORIA trial of vericiguat bolster previous data on the medication’s benefit by showing that 92% of patients hospitalized for a worsening heart failure event would be eligible to start the therapy and that doing so would reduce their risk of heart failure hospitalization and cardiovascular death, noted Stephen J. Greene, MD, Duke University Medical Center and the Duke Clinical Research Institute.